No Detail Found!

Expression Analysis of Matrix Metalloproteinase-9 Gene in Rheumatoid Arthritis Patients on Disease Modifying Anti-rheumatic Drugs.

Author(s)
Farzana Hakim Department of Biochemistry, Army Medical College, Rawalpindi, Pakistan
Amir Rashid Department of Biochemistry, Army Medical College, Rawalpindi, Pakistan
Amer Fakhr Department of Rheumatology, Military Hospital, Rawalpindi, Pakistan
Saleem Ahmed Khan Department of Pathology, Army Medical College, Rawalpindi, Pakistan
Abstract
Objective: To evaluate matrix metalloproteinase-9 gene expression in rheumatoid arthritis patients on disease modifying anti-rheumatic agents with the objective to further modify the current treatment regimen if indicated in order to prevent progression to deforming rheumatoid arthritis. Study Design: Cross-sectional comparative study. Place and Duration of Study: CREAM Lab (Centre for Research in Experimental and Applied Medicine) and Department of Biochemistry and Molecular Biology, Army Medical College, in collaboration with Rheumatology Department at Military Hospital Rawalpindi from November 2015 to November 2016. Methodology: A total of 60 patients of both genders were taken, among which 30 were patients and 30 were controls. Non-probability purposive sampling technique was used. RNA was extracted from respective blood sample and cDNA was synthesised and after optimisation, expression analysis of matrix metalloproteinase-9 gene was seen on real time PCR. Results: Mean age of rheumatoid arthritis patients and healthy controls was 49.27 ±12.11and 42.10 ±9.02 years, respectively. Among controls, 50% were males (15) and 50% were females (15); whereas, among patients, 30% (9) were males and 70% (21) were females. The mean cycle threshold (Ct) value of MMP-9 expressions in patients was 27.9147 ±2.953; whereas, mean Ct of controls was 23.84 ±2.845. Down regulation of this gene was found in patients in comparison to controls. Conclusion: Downregulation of matrix metalloproteinase-9 was observed in patients as compared to controls indicating that current treatment regimen did not require further modification.
Publication Details
Page(s) 902-905
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 28, Issue: 12, Year: 2018

Request the full text from PASTIC

References
HarveyR,FerrierD., 2010.Biochemistry (Lippincott's Illustrated Reviews Series),Lippincott Williams & Wilkins -
Gibofsky, 2012.A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis,Am J Manag Care 18 S295 -302
HameedK,GibsonT,KadirM,SultanaS,FatimaZ,SyedA, .The prevalence of rheumatoid arthritis in affluent and poor, -
FarooqiA,GibsonT., 1998.Prevalence of the major rheumatic disorders in the adult population of north Pakistan,Br J Rheumatol 37 491 -5
ShamimR,JanMD,ZafarU, 2015.Prevalenceof rheumatoid arthritis in population with arthralgia presenting to tertiary care,J Pak Med Assoc 65 1202 -5
JohnathanK,KatherineS. ACR, 2012.EULAR 2010 rheumatoid arthritis classification criteria,BS J Rheumatol 51 10 -
KailinaAN,OgorodovaLM,ChasovskikhI,KremerEE, 2013.Indices of matrix metalloproteinases (MMP-2, MMP-9, TIMP-1) with juvenile arthritis in children,Vestn Ross Akad Med Nauk 7 36 -40
LiG,ZhangY,QianY,ZhangH,GuoS,SunagawaM, 2013.Interleukin-17A promotes rheumatoid arthritis synoviocytes migration and invasion under hypoxia by increasing MMP2 and MMP9 expression through NF-kappaB/HIF-1alpha pathway,Mol Immunol 53 227 -36
GiannelliG,ErriquezR,IannoneF,MarinosciF,LapadulaG,AntonaciS., 2004.MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis,Clin Exp Rheumatol 22 335 -8
FiedorczykM,KlimiukPA,SierakowskiS,DomyslawskaI,ChwieckoJ, 2005.concentrations and markers of disease activity in early rheumatoid arthritis,Przegl Lek 62 1321 -4
de RooyDP,ZhernakovaA,TsonakaR,WillemzeA,KurreemanBA,TrynkaG, 2014.A genetic variant in the region of MMP-9 is associated with serum levels and progression of joint damage in rheumatoid arthritis,Ann Rheum Dis 73 1163 -9
KimWU,MinSY,ChoML,HongKH,ShinYJ,ParkSH, 2004.Elevated matrix metalloproteinase-9 in patients with systemic sclerosis,Arthritis Res Ther 7 R71 -
WeiST,SunYH,ZongSH,XiangYB, 2015.Serum levels of IL-6 and TNF- may correlate with activity and severity of rheumatoid arthritis,Medical Science Monitor: International Medical J Exp Clin Res 21 4030 -8
NgoST,SteynFJ,McCombePA, 2014.Gender differences in autoimmune disease,Front Neuroendocrinol 35 347 -69
BiverE,BeagueV,VerloopD,MolletD,LajugieD,BaudensG, 2009.Low and stable prevalence of rheumatoid arthritis in northern France,Revue du Rhumatisme 76 497 -500
YamanakaH,SugiyamaN,InoueE,TaniguchiA,MomoharaS., 2014.Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I),Mod Rheum 24 33 -40
YabluchanskiyA,MaY,IyerRP,HallME,LindseyML, 2013.Matrix metalloproteinase-9: Many shades of function in cardiovascular disease,Physiology 28 391 -403
XueM,McKelveyK,ShenK,MinhasN,MarchL,ParkS-Y, 2014.Endogenous MMP-9 and not MMP-2 promotes rheumatoid synovial fibroblast survival, inflammation and cartilage degradation,Rheumatology 53 2270 -9
HsiehMS,HoHC,ChouDT,PanS,LiangYC,HsiehTY, 2003.Expression of matrix metalloproteinase-9 (gelatinase B) in gouty arthritis and stimulation of MMP-9 by urate crystals in macrophages,J Cell Biochem 89 791 -9
XueM,MarchL,SambrookPN,JacksonCJ, 2007.Differential regulation of matrix metalloproteinase 2 and matrix metalloproteinase 9 by activated protein C: Relevance to inflammation in rheumatoid arthritis,Arthritis Rheum 56 2864 -74
SilosiI,CojocaruM,FoiaL,BoldeanuMV,PetrescuF, 2015.Significance of circulating and crevicular matrix metalloproteinase-9 in rheumatoid arthritis-chronic periodontitis association,J Immunol Res 218060 -
EdwardsCK,GreenJS,VolkHD,SchiffM,KotzinBL,MitsuyaH, 2012.Combined anti-tumor necrosis factor-alpha therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone,Front Immunol 3 366 -
TchetinaEV,PivanovaAN,MarkovaGA,LukinaGV,AleksandrovaEN,AleksankinAP, 2016.Rituximab downregulates gene expression associated with cell proliferation, survival, and proteolysis in the peripheral blood from rheumatoid arthritis patients: A link between high baseline autophagy-related ULK1 expression and improved pain control,Arthritis 12 -
0

Citations

0

Downloads

171

Views